Q Fever Medication

  • Author: Kelley Struble, DO; Chief Editor: Burke A Cunha, MD   more...
 
Updated: Jan 25, 2012
 

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications. Antimicrobial therapy is essential (though most cases of acute Q fever improve without intervention) to minimize risk of chronic Q fever. Prolonged antibiotic therapy is critical in managing chronic Q fever, although exact antibiotics recommended for use are in a state of flux. Consultation with an infectious disease specialist is recommended to assist in the choice of antibiotics. The best studied are combinations of doxycycline plus an additional antibiotic (eg, fluoroquinolone, rifampin, trimethoprim-sulfamethoxazole).

Patients with Q fever who are misdiagnosed with legionellosis have responded well to intravenous (IV) erythromycin, which probably is effective for pregnant patients, although no controlled trials have been performed. Some investigators use lysosomal alkalinizing agents (eg, hydroxychloroquine) for patients with chronic Q fever to increase the effectiveness of antibiotics.

Treatment of pregnant women is complicated. Infectious disease and obstetric consultations should be sought.

Next

Antibiotics, Other

Class Summary

Antibiotic drugs are used to provide in vivo or in vitro activity against Coxiella burnetii infections . However, empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the clinical setting.

Doxycycline is the drug of choice (DOC) in Q fever; however, in a series of pregnant patients with Q fever, trimethoprim-sulfamethoxazole (TMP-SMZ) was used with some success.[28] In the chronic setting, the addition of chloroquine to doxycycline may improve outcomes, although data are sparse.

Doxycycline (Vibramycin, Doryx, Monodox)

 

Doxycycline is the first-line agent for both acute and chronic Q diseases. This agent is a bacteriostatic drug that interferes with bacterial protein and cell-wall synthesis during active multiplication by binding to 30S ribosome. For severe cases, administer intravenously (IV); for outpatients, oral administration (PO) is preferred.

Ofloxacin

 

Ofloxacin is an alternative antibiotic to doxycycline in acute Q fever. This quinolone agent is a derivative of pyridine carboxylic acid with broad-spectrum bactericidal effect. Quinolones are effective in treating Q fever alone or when combined with doxycycline; consultation with an infectious disease specialist is recommended before its use.

Rifampin (Rifadin)

 

Rifampin is used to treat all forms of tuberculosis in combination with at least one other antituberculous drug. This agent inhibits RNA synthesis in bacteria by binding to the beta subunit of DNA-dependent RNA polymerase, which in turn blocks RNA transcription. Cross-resistance has only been shown with other rifamycins; combination therapy with doxycycline should be continued for chronic Q fever for at least 18 months.

Sulfamethoxazole and Trimethoprim (Bactrim, Bactrim DS, Septra DS)

 

Sulfamethoxazole and trimethoprim inhibits bacterial growth by inhibiting the synthesis of dihydrofolic acid. This would be a drug to use in pregnant women after consultation with the patient's obstetrician and an infectious disease specialist.

Azithromycin (Zithromax, Zmax)

 

Zithromax treats mild to moderate microbial infections by binding to the 50S ribosomal subunit of susceptible microorganisms and blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. Nucleic acid synthesis, however, is not affected.

This agent concentrates in phagocytes and fibroblasts, as demonstrated by in vitro incubation techniques. In vivo studies suggest that the concentration in phagocytes may contribute to drug distribution to inflamed tissues. Plasma concentrations are very low, but tissue concentrations are much higher, giving azithromycin value in treating intracellular organisms. This drug has a long tissue half-life.

Tetracycline

 

Tetracycline treats susceptible both gram-positive and gram-negative bacterial infections, as well as infections caused by species of Mycoplasma, Chlamydia, and Rickettsia. This agent inhibits bacterial protein synthesis by binding with the 30S and possibly 50S ribosomal subunits of susceptible bacteria.

Chloramphenicol

 

Chloramphenicol is used in patients who do not tolerate tetracycline. This agent binds to the 50S bacterial ribosomal subunits and inhibits bacterial growth by inhibiting protein synthesis. Chloramphenicol is effective against gram-negative and gram-positive bacteria. In severe cases, administer intravenously (IV); for outpatients, administer orally (PO).

Ciprofloxacin (Cipro)

 

Ciprofloxacin is a quinolone that is effective in treating Q fever alone or when combined with doxycycline. Consultation with an infectious disease specialist is recommended before its use.

Previous
Next

Antimalarials

Class Summary

Antimalarial agents are used for their alkalinizing action within the phagolysosomal compartment of monocytes, where C burnetii resides.

Hydroxychloroquine (Plaquenil)

 

Hydroxychloroquine is used in chronic Q fever with doxycycline, which is more effective. This agent results in fewer relapses than that with doxycycline and ofloxacin, and its treatment duration can be shortened. Hydroxychloroquine sulfate 200 mg is equivalent to 155 mg hydroxychloroquine base and 250 mg chloroquine phosphate.

Previous
Next

Analgesics, Other

Class Summary

Treatment of Q fever is symptomatic and supportive. Bed rest and mild analgesic-antipyretic therapy often help to relieve the lethargy, malaise, and fever associated with this disease.

Ibuprofen (Advil, Motrin, Caldolor, I-Prin)

 

Ibuprofen is usually the drug of choice (DOC) to treat mild to moderate headache unless contraindicated. This agent is also one of the few nonsteroidal anti-inflammatory drugs (NSAIDs) that is indicated for reduction of fever.

Acetaminophen (Tylenol, Feverall, Mapap, Aspirin Free Anacin)

 

Acetaminophen is the drug of choice (DOC) for treatment of pain in documented hypersensitivity to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and in gastrointestinal (GI) disease or with oral (PO) anticoagulants. This agent reduces fever by directly acting on hypothalamic heat-regulating centers, increasing the dissipation of body heat by vasodilation and sweating.

Previous
Next

Salicylates

Class Summary

Acetylsalicylic agents are effective in alleviating headaches, possibly because of their inhibition of prostaglandin synthesis.

Aspirin (Anacin, Ecotrin, Bayer Aspirin Extra Strength, Bufferin)

 

Aspirin is used to treat mild to moderate pain and headache. This agent blocks prostaglandin synthetase action, which in turn inhibits prostaglandin synthesis and prevents formation of platelet-aggregating thromboxane A2. Aspirin enhances dissipation of heat by vasodilating peripheral vessels, causing a decrease in body temperature, as well as acts on the hypothalamus heat-regulating center to reduce fever.

Previous
Next

Antitussives

Class Summary

Treatment of Q fever is symptomatic and supportive. Antitussives help to relieve the coughing associated with pneumonia, which is among the most common presenting symptoms. Few data on the effectiveness of expectorants outside the test tube have been reported. The prototype antitussive, codeine, was successfully used in models of chronic and induced cough, but clinical data for upper respiratory infections are limited. Existing data report the effectiveness of codeine to be somewhat equal to that of guaifenesin, dextromethorphan, or even placebo.

Dextromethorphan/guaifenesin (Mucinex DM, Robafen DM, Double Tussin DM)

 

Dextromethorphan is used for treatment of minor cough resulting from bronchial and throat irritation.

Benzonatate (Tessalon, Zonatuss)

 

Benzonatate is used for the symptomatic relief of cough. This agent suppresses cough by anesthetizing stretch receptors located in the respiratory passages, lungs, and pleura by dampening activity and reducing cough reflex.

Codeine/guaifenesin (Tussin-C, Allfen CD, ExeClear-C)

 

The combination of codeine and guaifenesin is used to treat minor cough resulting from bronchial and throat irritation.

Previous
 
Contributor Information and Disclosures
Author

Kelley Struble, DO  Fellow, Department of Infectious Diseases, University of Oklahoma College of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Alexandre Lacasse, MD, MSc  Internal Medicine Faculty, Assistant Director, Medicine Clinic, Infectious Disease Consultant, St Mary's Health Center

Alexandre Lacasse, MD, MSc is a member of the following medical societies: American College of Physicians, American Medical Association, Association of Program Directors in Internal Medicine, Infectious Diseases Society of America, and Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Kerry O Cleveland, MD  Associate Professor of Medicine, University of Tennessee College of Medicine; Consulting Staff, Department of Internal Medicine, Division of Infectious Diseases, Methodist Healthcare of Memphis

Kerry O Cleveland, MD is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America, and Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Hari Polenakovik, MD  Associate Professor of Medicine, Wright State University, Boonshoft School of Medicine

Hari Polenakovik, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Society for Microbiology, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, and Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Annie Ruest, MD, FRCPC  Consultant Physician in Infectious Diseases and Medical Microbiology, CHUQ-Hôtel-Dieu de Québec, Departments of Medicine and Medical Biology, Laval University Faculty of Medicine, Canada

Annie Ruest, MD, FRCPC is a member of the following medical societies: Canadian Infectious Disease Society and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Christian P Sinave, MD  Associate Professor, Department of Medical Microbiology and Infectious Diseases, University of Sherbrooke Faculty of Medicine, Canada

Christian P Sinave, MD is a member of the following medical societies: American Society for Microbiology and Canadian Infectious Disease Society

Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD  Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Additional Contributors

Leslie L Barton, MD Professor Emerita of Pediatrics, University of Arizona College of Medicine

Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Dan Danzl, MD Chair, Department of Emergency Medicine, Professor, University of Louisville Hospital

Dan Danzl, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Kentucky Medical Association, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Robert G Darling, MD, FACEP Clinical Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Director, Center for Disaster and Humanitarian Assistance Medicine

Robert G Darling, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, and Association of Military Surgeons of the US

Disclosure: Nothing to disclose.

Vinod K Dhawan, MD, FACP, FRCP(C) Professor, Department of Clinical Medicine, University of California, Los Angeles, David Geffen School of Medicine; Chief, Division of Infectious Diseases, Rancho Los Amigos National Rehabilitation Center, Downey, California.

Vinod K Dhawan, MD, FACP, FRCP(C) is a member of the following medical societies: American College of Physicians, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, and Royal College of Physicians and Surgeons of Canada

Disclosure: Pfizer Inc Honoraria Speaking and teaching

Jonathan A Edlow, MD Associate Professor of Medicine, Department of Emergency Medicine, Harvard Medical School; Vice Chairman, Department of Emergency Medicine, Beth Israel Deaconess Medical Center

Jonathan A Edlow, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Jon Mark Hirshon, MD, MPH Associate Professor, Department of Emergency Medicine, University of Maryland School of Medicine

Jon Mark Hirshon, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Public Health Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Joseph F John Jr, MD, FACP, FIDSA, FSHEA Clinical Professor of Medicine, Molecular Genetics and Microbiology, Medical University of South Carolina College of Medicine; Associate Chief of Staff for Education, Ralph H Johnson Veterans Affairs Medical Center

Disclosure: Nothing to disclose.

Rick Kulkarni, MD Attending Physician, Department of Emergency Medicine, Cambridge Health Alliance, Division of Emergency Medicine, Harvard Medical School

Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: WebMD Salary Employment

John M Leedom, MD Professor Emeritus of Medicine, Keck School of Medicine of the University of Southern California

John M Leedom, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Society for Microbiology, Infectious Diseases Society of America, International AIDS Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Geofrey Nochimson, MD Consulting Staff, Department of Emergency Medicine, Sentara Careplex Hospital

Geofrey Nochimson, MD is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

Robert L Norris, MD Associate Professor, Department of Surgery; Chief, Division of Emergency Medicine, Stanford University Medical Center

Robert L Norris, MD is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, California Medical Association, International Society of Toxinology, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Miller B Pearsall, MD Resident Physician and Clinical Assistant Instructor, Department of Emergency Medicine, State University of New York Downstate School of Medicine, Kings County Hospital Center, University Hospital of Brooklyn

Miller B Pearsall, MD is a member of the following medical societies: American College of Emergency Physicians and Emergency Medicine Residents Association

Disclosure: Nothing to disclose.

José Rafael Romero, MD Director of Pediatric Infectious Diseases Fellowship Program, Associate Professor, Department of Pediatrics, Combined Division of Pediatric Infectious Diseases, Creighton University/University of Nebraska Medical Center

José Rafael Romero, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, New York Academy of Sciences, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Richard H Sinert, DO Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Richard H Sinert, DO is a member of the following medical societies: American College of Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Russell W Steele, MD Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Jeter (Jay) Pritchard Taylor III, MD Compliance Officer, Attending Physician Emergency Medicine Residency, Department of Emergency Medicine, Palmetto Richland Memorial Hospital, University of South Carolina

Jeter (Jay) Pritchard Taylor III, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

References
  1. Centers for Disease Control and Prevention. Emergency preparedness and response: bioterrorism agents/diseases. Available at http://www.bt.cdc.gov/agent/agentlist-category.asp. Accessed October 6, 2011.

  2. Marrie TJ, Raoult D. Coxiella burnetii (Q fever). In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, Pa: Churchill Livingstone; 2005:2296-303.

  3. Samuel JE, Hendrix LR. Laboratory maintenance of Coxiella burnetii. Curr Protoc Microbiol. Nov 2009;Chapter 6:Unit 6C.1. [Medline].

  4. Raoult D, Stein A. Q fever during pregnancy: a risk for the mother, for the fetus and for the obstetrician. N Engl J Med. 1994;330:371.

  5. Ong C, Ahmad O, Senanayake S, Buirski G, Lueck C. Optic neuritis associated with Q fever: case report and literature review. Int J Infect Dis. Sep 2010;14 Suppl 3:e269-73. [Medline].

  6. Carcopino X, Raoult D, Bretelle F, Boubli L, Stein A. Q Fever during pregnancy: a cause of poor fetal and maternal outcome. Ann N Y Acad Sci. May 2009;1166:79-89. [Medline].

  7. Oyston PC, Davies C. Q fever: the neglected biothreat agent. J Med Microbiol. Jan 2011;60:9-21. [Medline].

  8. Marrie TJ, Stein A, Janigan D, Raoult D. Route of infection determines the clinical manifestations of acute Q fever. J Infect Dis. Feb 1996;173(2):484-7. [Medline].

  9. Marrie TJ. Q fever pneumonia. Infect Dis Clin North Am. Mar 2010;24(1):27-41. [Medline].

  10. Waag DM. Coxiella burnetii: host and bacterial responses to infection. Vaccine. Oct 16 2007;25(42):7288-95. [Medline].

  11. Cutler SJ, Bouzid M, Cutler RR. Q fever. J Infect. Apr 2007;54(4):313-8. [Medline].

  12. Hartzell JD, Wood-Morris RN, Martinez LJ, Trotta RF. Q fever: epidemiology, diagnosis, and treatment. Mayo Clin Proc. May 2008;83(5):574-9. [Medline].

  13. Raoult D, Tissot-Dupont H, Foucault C, et al. Q fever 1985-1998. Clinical and epidemiologic features of 1,383 infections. Medicine (Baltimore). Mar 2000;79(2):109-23. [Medline].

  14. World Health Organization. Report of a WHO Group of Consultants. Health aspects of chemical and biological weapons. Geneva, Switzerland: WHO Press; 1970.

  15. Karakousis PC, Trucksis M, Dumler JS. Chronic Q fever in the United States. J Clin Microbiol. Jun 2006;44(6):2283-7. [Medline]. [Full Text].

  16. Centers for Disease Control and Prevention. Potential for Q fever infection among travelers returning from Iraq and the Netherlands. Available at http://emergency.cdc.gov/HAN/han00313.asp. Accessed May 12, 2010.

  17. Schimmer B, Morroy G, Dijkstra F, et al. Large ongoing Q fever outbreak in the south of The Netherlands, 2008. Euro Surveill. Jul 31 2008;13(31):[Medline]. [Full Text].

  18. Dupuis G, Petite J, Péter O, Vouilloz M. An important outbreak of human Q fever in a Swiss Alpine valley. Int J Epidemiol. Jun 1987;16(2):282-7. [Medline].

  19. Terheggen U, Leggat PA. Clinical manifestations of Q fever in adults and children. Travel Med Infect Dis. May 2007;5(3):159-64. [Medline].

  20. Scola BL. Current laboratory diagnosis of Q fever. Semin Pediatr Infect Dis. Oct 2002;13(4):257-62. [Medline].

  21. Raoult D, Houpikian P, Tissot Dupont H, et al. Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med. Jan 25 1999;159(2):167-73. [Medline].

  22. Healy B, Llewelyn M, Westmoreland D, Lloyd G, Brown N. The value of follow-up after acute Q fever infection. J Infect. Apr 2006;52(4):e109-12. [Medline].

  23. Fenollar F, Raoult D. Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria. Int J Antimicrob Agents. Nov 2007;30 Suppl 1:S7-15. [Medline].

  24. Healy B, van Woerden H, Raoult D, et al. Chronic Q fever: different serological results in three countries--results of a follow-up study 6 years after a point source outbreak. Clin Infect Dis. Apr 15 2011;52(8):1013-9. [Medline].

  25. Brouillard JE, Terriff CM, Tofan A, Garrison MW. Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents. Pharmacotherapy. Jan 2006;26(1):3-14. [Medline].

  26. Moodie CE, Thompson HA, Meltzer MI, Swerdlow DL. Prophylaxis after exposure to Coxiella burnetii. Emerg Infect Dis. Oct 2008;14(10):1558-66. [Medline]. [Full Text].

  27. Parker NR, Barralet JH, Bell AM. Q fever. Lancet. Feb 25 2006;367(9511):679-88. [Medline].

  28. Raoult D, Fenollar F, Stein A. Q fever during pregnancy: diagnosis, treatment, and follow-up. Arch Intern Med. Mar 25 2002;162(6):701-4. [Medline].

Previous
Next
 
A: Chest radiograph with normal findings. B: Chest radiograph demonstrating Q fever pneumonia.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.